{"id":280259,"date":"2025-07-22T09:00:59","date_gmt":"2025-07-22T13:00:59","guid":{"rendered":"https:\/\/rarediseases.org\/?p=280259"},"modified":"2025-07-21T16:15:48","modified_gmt":"2025-07-21T20:15:48","slug":"national-organization-for-rare-disorders-announces-new-board-members","status":"publish","type":"post","link":"https:\/\/rarediseases.org\/es\/national-organization-for-rare-disorders-announces-new-board-members\/","title":{"rendered":"National Organization for Rare Disorders Announces New Board Members"},"content":{"rendered":"

QUINCY, Mass., July 22, 2025\u2014<\/b><\/strong>The National Organization for Rare Disorders (NORD\u00ae), a leading rare disease nonprofit patient advocacy organization, welcomes two new members to the Board of Directors: Steven Mah, Ph.D., and Alan M. Miller, M.D., Ph.D.<\/span>\u00a0<\/span><\/p>\n

Dr. Mah most recently served as a Senior Research Analyst at TD Securities and brings more than two decades of experience spanning finance and scientific research. Dr. Miller, a board-certified medical oncologist, who c<\/span>urrently serves as the Chief Medical Officer at Translational Drug Development (TD2),<\/span> offers <\/span>deep expertise in rare cancers, clinical trials, and academic research.<\/span>\u00a0<\/span>\u00a0<\/span><\/p>\n

\u201cIn the face of mounting challenges to scientific research and access to affordable health care, our commitment to the rare disease community has never been stronger,\u201d said NORD Chief Executive Officer Pamela Gavin. \u201cThe rare disease community \u2013 more than 30 million Americans strong \u2013 is counting on us to keep fighting for them, and Drs. Mah and Miller have a vital role to play in this work.\u201d<\/span>\u00a0<\/span><\/p>\n

A published scientist and inventor, with multiple peer-reviewed publications and patents in genetics and drug development, Dr. Mah most recently served as a Senior Research Analyst at TD Securities, where his work was concentrated on emerging life science tools and technologies such as AI-driven drug discovery, synthetic biology, and cell and gene therapy. His financial experience spans equity research and health care investment banking, advising both public and private companies on strategic growth and partnerships.\u00a0<\/span>\u00a0<\/span><\/p>\n

Dr. Mah, a native of Katonah, N.Y., holds a doctorate in molecular biology from the Salk Institute\/University of California-San Diego, a master\u2019s in business from Cornell University\u2019s Johnson Graduate School of Management, and a bachelor\u2019s degree in molecular biology from the University of California, Los Angeles.\u00a0<\/span>\u00a0<\/span><\/p>\n

\u201cI\u2019m deeply passionate about advancing research and supporting the rare disease community,\u201d said Dr. Mah. \u201cDuring my time as a research analyst, I\u2019ve seen firsthand how developments in rare disease research impact patients\u2019 lives. I look forward to collaborating with my fellow Board members and contributing my experience to support NORD\u2019s mission by advancing care, research, and policy for the rare disease community.\u201d<\/span>\u00a0<\/span><\/p>\n

With over<\/span> three decades of experience building and leading high-impact cancer programs across academic institutions and large health care systems, Dr. Miller, who hails from Erie, Colo., has successfully developed system-wide oncology networks, established clinical trial infrastructures, and overseen the creation of major cancer centers.<\/span>\u00a0<\/span>\u00a0<\/span><\/p>\n

He<\/span> has held such prominent roles as Chief Medical Director of Oncology at SCL Health (now known as Intermountain Health, a nonprofit health system serving six western states), Chief of Oncology at Baylor Scott & White Health, and Associate Senior Vice President for Health Sciences at Tulane University.\u00a0<\/span>\u00a0<\/span><\/p>\n

In addition to serving on NORD\u2019s Board of Directors, Dr. Miller also joins NORD\u2019s Scientific and Medical Advisory Committee, which provides thought leadership and scientific and medical input to guide NORD\u2019s work in policy, research, and care.<\/span>\u00a0<\/span><\/p>\n

\u201cAs both a physician and a researcher, I understand the urgency of developing effective treatments for people living with cancer, especially rare cancers,\u201d said Dr. Miller. \u201cBy partnering with my fellow Board and Advisory Committee members, we can combine our knowledge and expertise to support critical advancements in clinical trials and drug development, bringing new hope to those living with rare diseases.\u201d<\/span>\u00a0<\/span><\/p>\n

To learn more about NORD, visit <\/span>rarediseases.org<\/span><\/a>.\u00a0<\/span>\u00a0<\/span><\/p>\n

To learn more about NORD\u2019s Board of Directors, visit <\/span>rarediseases.org\/about-us\/board-of-directors\/<\/span><\/a>.\u00a0<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

QUINCY, Mass., July 22, 2025\u2014The National Organization for Rare Disorders (NORD\u00ae), a leading rare disease nonprofit patient advocacy organization, welcomes two new members to the Board of Directors: Steven Mah, … <\/p>\n

Continue reading “National Organization for Rare Disorders Announces New Board Members”<\/span><\/a><\/p>\n","protected":false},"author":37,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[2394,504],"tags":[],"class_list":["post-280259","post","type-post","status-publish","format-standard","hentry","category-nordinthenews","category-press-releases"],"acf":[],"_links":{"self":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts\/280259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/comments?post=280259"}],"version-history":[{"count":0,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts\/280259\/revisions"}],"wp:attachment":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/media?parent=280259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/categories?post=280259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/tags?post=280259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}